Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome
The company’s DELVE™ Platform combines computation and high-throughput biology to systematically discover the therapeutic potential of proteins tuned through millennia of viral evolution
The company emerges after three years of platform development with an initial commitment of
"We asked, what if we could expand beyond the functional boundaries of the human proteome by harnessing viral evolution,” said
Prologue is unlocking viral proteome-assisted drug discovery with its novel DELVE Platform. DELVE combines computation and high-throughput biology to continually mine the expanding viral proteome to uncover viral proteins and their unique features and evaluate their potential to modulate human physiology for the treatment of disease. The platform contains the largest known database of viral protein structures layered both with detailed data from known human proteins and annotations of previously uncharacterized viral proteins predicted through Prologue’s proprietary computational frameworks. By applying the learned rules of natural viral evolution, Prologue creates enhanced therapeutic proteins programmed to have properties, some previously unique to viruses, that expand the functional boundaries of human proteins.
“The viral proteome dwarfs the human proteome by orders of magnitude, enabling us to reveal a trove of powerful new proteins that can be used as medicines across nearly any therapeutic area,” said
In addition to Afeyan and Afzelius, Prologue is led by
About Prologue Medicines
Prologue is designing powerful new medicines by unlocking the viral proteome. The company’s state-of-the-art DELVE™ Platform systematically identifies and evaluates viral proteins and their unique features for their potential to precisely regulate human physiology. By co-opting viral evolution, Prologue is expanding the functional boundaries of proteins encoded by the human genome to create new programmable medicines. Prologue was founded by Flagship Pioneering in 2021.
About Flagship Pioneering
Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507928628/en/
Media:
press@flagshippioneering.com
Source: Prologue Medicines